American Express Launches 2021 Global Travel Trends Report
9.3.2021 14:00:00 EET | Business Wire | Press release
American Express (NYSE: AXP) released the American Express Travel: Global Travel Trends Report today, which provides unique insight into consumer sentiment toward travel nearly one year after the COVID-19 pandemic began. The findings in the report, grounded in survey research across seven countries, including the United States, Australia, India, Canada, Mexico, Japan and the United Kingdom1, demonstrates that consumers are looking forward to traveling again and that they are planning for future trips.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005322/en/
American Express Travel: Global Travel Trends Report Finds Consumers are Looking Forward to Traveling Again (Graphic: Business Wire)
Top insights include:
- Strong Pent-Up Demand for Travel: 87% of people surveyed said that having a trip planned in the future gives them something to look forward to, 76% of respondents are creating their destination wish list for future travel even though they might not be able to travel yet and 63% of respondents said that they are saving their credit card points so they can go on a vacation once they feel comfortable traveling.
- Ready to Book Now: 56% of respondents said that they miss traveling so much that they are willing to book a trip now even if they might have to cancel it in the future.
- Rise of The Digital Nomad: 54% of respondents said that the freedom and flexibility of being able to live and work while traveling the globe is more appealing now than it was prior to the pandemic.
- Safety is a Priority: 65% of respondents said they plan to travel after they and their family members have received a vaccine for COVID-19.
- Privacy is the New Ultimate Luxury: 75% of respondents agree that the experiences that offer ultimate privacy is becoming a key sought-after feature of luxury travel.
- Increase in Sustainable Travel: 68% of respondents agree they are trying to be more aware of sustainability-friendly travel brands to support.
“Our latest global trends report shows that there is a pent-up demand for travel among consumers, with many people longing for and beginning to plan future trips,” said Audrey Hendley, President of American Express Travel. “In addition, the pandemic environment is giving rise to emerging trends, such as the increasing appeal of working from anywhere while traveling globally, luxury being defined as more personalized experiences, cleanliness and privacy as the ultimate luxury amenities, as well as a growing interest in the environmental and social purpose of their trips and travel companies.”
Here’s a look at key findings from the report:
CONSUMERS ARE LOOKING FORWARD TO TRAVELING AGAIN
People are finding hope and comfort in thinking about and even planning future trips.
- Travel to Uplift Health & Wellness: 78% of respondents indicate wanting to travel in 2021 to relieve the stresses from 2020.
- Planning and Paying for Future Travel: One in three say they will more frequently use travel credits or points to pay for all or part of a trip in 2021 than they did prior to the COVID-19 pandemic.
- Making Up for Missed Travel: 61% of survey respondents plan to spend more than they normally would on a trip in 2021 since they could not travel in 2020.
- Consumers Willing to Make Sacrifices to Travel: 64% of respondents miss traveling so much that they would be willing to give up social media for a month to be able to go on vacation.
- Culinary Tourism is Here to Stay: 62% of respondents say that eating is the top activity they are interested in doing while traveling, and American Express Travel booking data for January 2021 shows foodie centric cities as top destinations for U.S. and International Card Members. Miami, San Francisco, Chicago and Houston are hot spots for U.S. American Express Card Members2 whereas Mexico City, Singapore and Tokyo are topping the list for International American Express Card Members3.
THE NEW TRAVEL MINDSET
With regular changes to booking policies, travel offers, and new destinations to consider, there is a new travel mindset today.
- Luxury Travel: The pandemic has changed peoples’ perception of luxury travel with personalized experiences (82%), high cleanliness standards (81%) and privacy (79%) being the most desirable luxury amenities among respondents1. 59% indicate that they want to use a travel agent to help plan and customize their next trip and 80% indicate they are willing to travel to destinations during the offseason so that it's less crowded.
- Surge in ‘Second-City’ Destinations: 69% of respondents are interested in visiting lesser-known destinations and American Express Travel booking data reinforces this trend, showing a rise in reservations for second-city destinations. For example, Dallas and Charlotte saw a higher share of bookings from International Card Members in January 2021 than the previous year4 and American Express Travel consultants are seeing requests for smaller cities like Porto (instead of Lisbon) in Portugal, and Wellington (instead of Auckland) in New Zealand.
TRAVELING WITH PURPOSE
Consumers are becoming more conscious travelers, are more aware of travel companies aligned with their values and will journey to destinations where they can have a positive impact on communities.
- Backing Local Communities: 72% of respondents agree that they are passionate about traveling to destinations to help boost tourism revenue and the local economy1.
- Supporting Travel Brands that Prioritize Diversity & Inclusion: 69% of respondents agree that they want to choose an airline/hotel that values diversity and inclusion, and whose employees reflect a diverse customer base.
- Carbon Conscious Travelers: 60% of respondents agree they want to book airlines that have a carbon neutral commitment.
American Express Travel’s 4,500 travel consultants provide customers with world-class service, where high-tech meets high-touch support, 24/7. To give customers more value and confidence whenever they’re ready to travel, the company has rolled out a number of discounts and offers across hotel, air and car rentals and extended American Express Travel cancellation fee waivers through the end of September. To find out more visit AmexTravel.com.
For additional findings and more information on the American Express Travel: Global Travel Trends Report, visit here.
AMERICAN EXPRESS TRAVEL: GLOBAL TRAVEL TRENDS REPORT METHODOLOGY
1 This Amex Trendex online poll was conducted by Morning Consult between January 15-24, 2021 among a national sample of 1,000 travelers in Australia, Canada, India, Japan, Mexico and the U.K., and 2,000 in the U.S. $70k+ USD household income (HHI) equivalent in Australia, Canada, Japan, the U.K. and the U.S., $50k+ USD equivalent HHI in Mexico, and $20k+ USD equivalent household income in India. Travelers defined as adults who traveled by air at least once in 2019. Results have a margin of error of plus or minus 2 percentage points in the U.S.; plus or minus 3 percentage points in the other countries.
2 Based on U.S. Card Member flight and hotel bookings made through American Express Travel in January 2021
3 Based on International Card Member flight and hotel bookings made through American Express Travel in January 2021
4 Based on International Card Member hotel and air bookings made through American Express Travel in January 2021 compared to January 2020.
ABOUT AMERICAN EXPRESS
American Express is a globally integrated payments company, providing customers with access to products, insights and experiences that enrich lives and build business success. Learn more at americanexpress.com and connect with us on facebook.com/americanexpress, instagram.com/americanexpress, linkedin.com/company/american-express, twitter.com/americanexpress, and youtube.com/americanexpress.
Key links to products, services and corporate responsibility information: charge and credit cards, business credit cards, travel services, gift cards, prepaid cards, merchant services, Accertify, InAuth, corporate card, business travel, and corporate responsibility.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005322/en/
Contact information
AMERICAN EXPRESS
Heather Norton
Heather.A.Norton@aexp.com
Ali Pearce
Ali.Pearce@aexp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release
Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
